Abstract 1136P
Background
There are no active treatment options for patients (pts) with progressive melanoma brain metastases (MBM) who have failed treatment with immune checkpoint blockade (ICB) and BRAF-/MEK-inhibitors (BRAF/MEKi). Regorafenib (REGO), an oral multi-target kinase inhibitor (incl. inhibition of RAF-dimers), has single-agent activity in pretreated melanoma (VD Mijnsbrugge et al. SMR 2022).
Methods
We report our single center retrospective review of prospectively registered pts with refractory MBM treated with REGO and BRAF/MEKi.
Results
17 pts with stage IV-M1d melanoma were included (8F; med age 54y [33-75]; WHO PS: 0/1/2/3 resp. n=3/6/6/2 pts; 13 pts BRAFmt (12 BRAF V600mt, 1 BRAF fusion), 4 pts NRAS Q61mt). All pts previously progressed on ICB, BRAF/MEKi (all BRAFmt pts), chemotherapy (4 pts), T-VEC (2 pts), REGO mono (3 pts), and REGO + ICB (2 pts). At baseline, 15 pts had active MBM (8 pts were on steroids); 4 pts had intracranial evaluable disease only. BRAFmt pts were treated with REGO (40-80 mg QD) combined with BRAF/MEKi, NRASmt pts with REGO + MEKi (+ low-dose BRAFi to mitigate skin toxicity). There were no grade >4 TRAE. Grade 3 TRAE included arterial hypertension (n=4), and hepatotoxicity (n=2). None of the 2 pts without active MBM at baseline progressed intra-cranially. The best objective intracranial response (according to RANO-BM) in 17 response evaluable pts was: PR in 5 pts (29%; incl. 4 BRAFmt pts), and SD in 5 pts (29%; incl. 4 BRAFmt pts). In 5 pts intra- and extracranial disease control (PR, SD) were concordant. 3 pts with PR intra- had SD extra-cranially; 2 pts with SD intra- had PD extra-cranially. Assuming a potential clinical benefit of therapy beyond first PD, 10 out of 16 progressive pts continued treatment and remained clinically stable for an additional 3-48 weeks (w) (median 7w). Median time on REGO+BRAF/MEKi in BRAFmt pts was 13w [range 3-62], and 27.5w [range 3-56] on REGO + MEKi in NRASmt pts. In 3 pts treatment is ongoing (9-62w after initiation). Median PFS and OS is resp. 8.4w and 24.6w in BRAFmt pts; 8.6w and 10.1w in NRASmt pts.
Conclusions
In heavily pretreated patients with refractory MBM, REGO combined with BRAF/MEKi demonstrated promising anti-tumor activity. Further investigation in a prospective trial is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bart Neyns.
Funding
Has not received any funding.
Disclosure
I. Dirven: Non-Financial Interests, Institutional, Product Samples, Drug support only for investigator-sponsored single-centre clinical trial: Bayer; Non-Financial Interests, Institutional, Non-financial benefits, Travel, accommodation, and expenses: AstraZeneca. J. Tijtgat: Financial Interests, Institutional, Advisory Board: Novartis. B. Neyns: Financial Interests, Institutional, Advisory Board: Novartis, Bristol Myers Squibb, Pierre Fabre, MSD (Merck Sharp & Dohme); Financial Interests, Institutional, Research Grant: Novartis, Pfizer; Non-Financial Interests, Institutional, Product Samples: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
1181TiP - BEPCOME-MB: Treatment of BRAFV600 mutated melanoma brain metastases with encorafenib + binimetinb + pembrolizumab with or without stereotactic radiosurgery
Presenter: Philippe Saiag
Session: Poster session 13
1188P - Landscape of Delta-like-ligand 3 (DLL3) expression across neuroendocrine neoplasms (NENs)
Presenter: Anthony Crymes
Session: Poster session 13
1189P - Mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN): Characterization of the genomic and pathological profile
Presenter: Annabella Di Mauro
Session: Poster session 13
1191P - TTF-1 expression in lung neuroendocrine tumors (NET): A gender-related biomarker
Presenter: Anna La Salvia
Session: Poster session 13
1192P - Smoking adversely affects survival of metastatic lung carcinoid patients: Analysis of a large international audit
Presenter: Sara Valpione
Session: Poster session 13
1193P - Evaluation of treatment appropriateness in patients submitted to surgery for non-functioning pancreatic neuroendocrine tumors (NF-PanNETs)
Presenter: Anna Battistella
Session: Poster session 13
1194P - Do metastatic appendiceal NETs ever develop metachronously after appendectomy or right hemicolectomy?
Presenter: Taymeyah Al-Toubah
Session: Poster session 13
1195P - Neuroendocrine Tumors (NETs): How Big Data (BD) techniques applied to Electronic Health Records (EHR) can improve our understanding of this patient population
Presenter: Jorge Hernando
Session: Poster session 13
1196P - Regional lymph node metastasis risk factors for rectal neuroendocrine tumors: A population-based study
Presenter: Dan Cao
Session: Poster session 13
1197P - Somatostatin analogs or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors
Presenter: Maria Grazia Maratta
Session: Poster session 13